These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18220820)

  • 1. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
    Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
    Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation.
    Itzkowitz SH; Yio X
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G7-17. PubMed ID: 15194558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes.
    Tomasello G; Tralongo P; Damiani P; Sinagra E; Di Trapani B; Zeenny MN; Hussein IH; Jurjus A; Leone A
    World J Gastroenterol; 2014 Dec; 20(48):18121-30. PubMed ID: 25561781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives.
    Romano M; DE Francesco F; Zarantonello L; Ruffolo C; Ferraro GA; Zanus G; Giordano A; Bassi N; Cillo U
    Anticancer Res; 2016 Apr; 36(4):1447-60. PubMed ID: 27069120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.
    Azer SA
    Eur J Gastroenterol Hepatol; 2013 Mar; 25(3):271-81. PubMed ID: 23169309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and colorectal cancer.
    Kraus S; Arber N
    Curr Opin Pharmacol; 2009 Aug; 9(4):405-10. PubMed ID: 19589728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
    Perera AP; Kunde D; Eri R
    Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Inflammation in the Development of Colorectal Cancer.
    Muthusami S; Ramachandran IK; Babu KN; Krishnamoorthy S; Guruswamy A; Queimado L; Chaudhuri G; Ramachandran I
    Endocr Metab Immune Disord Drug Targets; 2021; 21(1):77-90. PubMed ID: 32901590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal inflammation and colorectal cancer: a double-edged sword?
    Rizzo A; Pallone F; Monteleone G; Fantini MC
    World J Gastroenterol; 2011 Jul; 17(26):3092-100. PubMed ID: 21912451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic targets for inflammatory bowel disease.
    Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
    J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
    Kim ER; Chang DK
    World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saponins regulate intestinal inflammation in colon cancer and IBD.
    Dong J; Liang W; Wang T; Sui J; Wang J; Deng Z; Chen D
    Pharmacol Res; 2019 Jun; 144():66-72. PubMed ID: 30959159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IBD immunopathogenesis: A comprehensive review of inflammatory molecules.
    Park JH; Peyrin-Biroulet L; Eisenhut M; Shin JI
    Autoimmun Rev; 2017 Apr; 16(4):416-426. PubMed ID: 28212924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides as Therapeutic Agents for Inflammatory-Related Diseases.
    La Manna S; Di Natale C; Florio D; Marasco D
    Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease.
    Zhang L; Ocansey DKW; Liu L; Olovo CV; Zhang X; Qian H; Xu W; Mao F
    Biomed Pharmacother; 2021 Aug; 140():111752. PubMed ID: 34044275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.
    Zatorski H; Sałaga M; Fichna J
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Nov; 392(11):1321-1330. PubMed ID: 31359088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic inflammatory bowel disease and cancer.
    Pohl C; Hombach A; Kruis W
    Hepatogastroenterology; 2000; 47(31):57-70. PubMed ID: 10690586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential role of nutraceutical compounds in inflammatory bowel disease.
    Larussa T; Imeneo M; Luzza F
    World J Gastroenterol; 2017 Apr; 23(14):2483-2492. PubMed ID: 28465632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the immunological effects of food bioactive peptides in animal models of intestinal inflammation.
    de Medina FS; Daddaoua A; Requena P; Capitán-Cañadas F; Zarzuelo A; Dolores Suárez M; Martínez-Augustin O
    Proc Nutr Soc; 2010 Aug; 69(3):454-62. PubMed ID: 20598199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.